This video highlights research into the use of post-transplant therapies to prevent or treat disease recurrence following allogeneic stem cell transplantation.
Venetoclax has durable clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.
The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies.
In this interview, we discuss a mathematical model that was created to predict patient response to immunotherapy for cancer treatment.
Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.
Use of a brief educational video increased hairdressers’ knowledge of melanoma detection and improved their self-confidence to detect skin lesions.
The FDA approved bosutinib (Bosulif) for use as a treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia.
The FDA has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer.
A recent analysis from the Breast Cancer Surveillance Consortium revealed that community oncology practices are neglecting to use MRI screening for at-risk women, and lower-risk women are being unnecessarily screened.
In this interview we discuss a study that examined the risk of acute myeloid leukemia in thyroid cancer patients who have been treated with surgery and radioiodine therapy vs those treated with surgery alone.
The addition of tumor-treating fields to maintenance temozolomide chemotherapy significantly delayed progression and improved overall survival in patients with glioblastoma who had received standard radiochemotherapy compared with maintenance temozolomide alone.
A combination of the FLT3 kinase inhibitor quizartinib with 5-azacitidine or low-dose cytarabine is active in patients with FLT3-ITD mutated myeloid leukemias, according to a new study.
In this slide show we highlight some of the top news on lung cancer in 2017, including FDA approvals, a new standard of care for ALK-positive lung cancer, increased risk with vitamin B supplements, and more.
The addition of pazopanib to paclitaxel failed to improve outcomes over paclitaxel alone in women with persistent or recurrent epithelial ovarian cancer.
A new study has found that there are significant gaps in participation among people aged 75 and older in clinical trials of hematologic malignancies when considered against the incidence of these malignancies in this age group.